Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression The enrollment goal of 125 patients was met. Median age was 46 years (range, 21-65 years), ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results